Breaking News Instant updates and real-time market news.

HRTX

Heron Therapeutics

$12.50

-1 (-7.41%)

08:34
01/12/17
01/12
08:34
01/12/17
08:34

Heron Therapeutics announces submission of NDA for Cinvanti, or HTX-019

Heron Therapeutics announced submission of the New Drug Application for CINVANTI, or HTX-019, the first polysorbate 80-free, intravenous formulation of aprepitant for the prevention of CINV, to the U.S. Food and Drug Administration. Aprepitant belongs to a class of agents known as NK1 receptor antagonists, which are often used in combination with 5-HT3 receptor antagonists for the prevention of CINV. The NDA filing includes data demonstrating the bioequivalence of CINVANTI to EMEND IV, supporting its efficacy for the prevention of both acute and delayed CINV with both moderately emetogenic chemotherapy and highly emetogenic chemotherapy. Results also showed CINVANTI was better tolerated than EMEND IV, with significantly fewer adverse events reported with CINVANTI.

  • 12

    Jan

HRTX Heron Therapeutics
$12.50

-1 (-7.41%)

11/09/16
COWN
11/09/16
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics price target lowered to $40 from $47 at Cowen
Cowen analyst Boris Peaker lowered his price target on Heron Therapeutics (HRTX) to $40 from $47 following the company's Q3 results. The analyst expects a slow sales ramp for Sustol due to competition, reimbursement dynamics, and Tesaro's (TSRO) early experience with its launch of Varubi. Peaker maintained his Outperform rating on Heron Therapeutics shares.
01/05/17
JEFF
01/05/17
NO CHANGE
Target $29
JEFF
Buy
Heron Therapeutics price target lowered to $29 from $40 at Jefferies
Jefferies analyst Biren Amin lowered his price target for Heron Therapeutics to $29 after the company guided to 2017 Sustol sales of $15M-$25M, below the consensus of $46M. The outlook conservatively reflects a slow launch which is "largely baked into current prices," Amin tells investors in a research note. The analyst keeps a Buy rating on Heron.
01/05/17
LEER
01/05/17
NO CHANGE
Target $21
LEER
Outperform
Heron Therapeutics price target lowered to $21 from $34 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Heron Therapeutics to $21 from $34 to reflect lower Sustol forecasts and as he now assumes the company will need to raise capital at lower valuations versus his prior assumptions. The analyst notes that Heron Therapeutics provided several clinical and corporate updates which improve his confidence around the HTX-011 program for post-operative pain but diminish his outlook for Sustol in chemo induced nausea and vomiting. He reiterates an Outperform rating on the shares.
01/05/17
COWN
01/05/17
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker noted Heron Therapeutics released positive Phase 2 abdominoplasty data for HTX-011 but acknowledged the company is a magnet for controversy. The miss on statistical significance at 0-24 hours, as well as Sustol guidance, may create temporary weakness in the shares, said Peaker, who would view the weakness as a buying opportunity. Peaker reiterated his Outperform rating and $40 price target on Heron Therapeutics shares.

TODAY'S FREE FLY STORIES

STLD

Steel Dynamics

$39.85

0.01 (0.03%)

18:07
12/15/17
12/15
18:07
12/15/17
18:07
Earnings
Steel Dynamics sees Q4 EPS 48c-52c, consensus 55c »

"Despite a lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

House plans to vote…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Republicans release final tax bill proposal, CNBC reports »

Republicans have released…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$162.60

5.4 (3.44%)

17:37
12/15/17
12/15
17:37
12/15/17
17:37
Hot Stocks
McKesson awarded $400M government contract »

McKesson has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$60.94

0.11 (0.18%)

17:34
12/15/17
12/15
17:34
12/15/17
17:34
Syndicate
Breaking Syndicate news story on Ameren »

Ameren files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$57.76

1 (1.76%)

, AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

17:33
12/15/17
12/15
17:33
12/15/17
17:33
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Akamai (AKAM), up…

AKAM

Akamai

$57.76

1 (1.76%)

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

PG

Procter & Gamble

$91.89

0.89 (0.98%)

PETX

Aratana Therapeutics

$5.73

0.15 (2.69%)

HPE

HP Enterprise

$14.41

0.17 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 13

    Dec

GRMN

Garmin

$58.36

-1.1 (-1.85%)

17:32
12/15/17
12/15
17:32
12/15/17
17:32
Recommendations
Garmin analyst commentary at Tigress Financial »

Garmin growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$322.82

5.81 (1.83%)

17:26
12/15/17
12/15
17:26
12/15/17
17:26
Hot Stocks
Lockheed Martin awarded $135.83M government contract »

Lockheed Martin is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

PG

Procter & Gamble

$91.89

0.89 (0.98%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
Peltz to join Procter & Gamble board effective March 1, 2018 »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.89 (0.98%)

, NVS

Novartis

$84.86

0.39 (0.46%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
P&G names Trian's Nelson Peltz, Novartis CEO Jimenez to board »

Procter & Gamble (PG)…

PG

Procter & Gamble

$91.89

0.89 (0.98%)

NVS

Novartis

$84.86

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 17

    May

SNSS

Sunesis

$3.36

0.16 (5.00%)

17:16
12/15/17
12/15
17:16
12/15/17
17:16
Hot Stocks
Sunesis CEO Swisher to resign, Dayton Misfeldt named interim CEO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, BA

Boeing

$293.94

0.06 (0.02%)

17:09
12/15/17
12/15
17:09
12/15/17
17:09
Hot Stocks
AT&T CEO Stephenson resigns from Boeing board »

According to a regulatory…

T

AT&T

$38.24

0.5 (1.32%)

BA

Boeing

$293.94

0.06 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

HPE

HP Enterprise

$14.41

0.17 (1.19%)

17:03
12/15/17
12/15
17:03
12/15/17
17:03
Syndicate
Breaking Syndicate news story on HP Enterprise »

HP Enterprise files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

FSV

FirstService

$67.87

-0.54 (-0.79%)

17:02
12/15/17
12/15
17:02
12/15/17
17:02
Hot Stocks
Breaking Hot Stocks news story on FirstService »

Jay S. Hennick reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETP

Energy Transfer Partners

$17.50

0.08 (0.46%)

17:01
12/15/17
12/15
17:01
12/15/17
17:01
Hot Stocks
Energy Transfer gets FERC approval to place Rover Pipeline's 1B into service »

Energy Transfer Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

, BTC

Bitcoin

16:56
12/15/17
12/15
16:56
12/15/17
16:56
Periodicals
TD Ameritrade to offer bitcoin futures, CNBC reports »

TD Ameritrade will now…

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HIIQ

Health Insurance Innovations

$26.90

-0.65 (-2.36%)

16:55
12/15/17
12/15
16:55
12/15/17
16:55
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Cannell Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$24.96

0.13 (0.52%)

16:51
12/15/17
12/15
16:51
12/15/17
16:51
Hot Stocks
Breaking Hot Stocks news story on Regional Management »

Basswood Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBY

NovaBay

$3.35

-0.0668 (-1.96%)

16:50
12/15/17
12/15
16:50
12/15/17
16:50
Syndicate
NovaBay files to sell $12M of common stock »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, TWX

Time Warner

$90.25

0.6 (0.67%)

16:50
12/15/17
12/15
16:50
12/15/17
16:50
Periodicals
DOJ, AT&T held unsuccessful settlement talks, Reuters reports »

The U.S. Department of…

T

AT&T

$38.24

0.5 (1.32%)

TWX

Time Warner

$90.25

0.6 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$6.06

0.2 (3.41%)

16:48
12/15/17
12/15
16:48
12/15/17
16:48
Syndicate
Breaking Syndicate news story on Sunrun »

Sunrun files to sell 30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$6.06

0.2 (3.41%)

16:47
12/15/17
12/15
16:47
12/15/17
16:47
Syndicate
Breaking Syndicate news story on Sunrun »

Sunrun files $328.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SINO

Sino-Global

$2.59

0.05 (1.97%)

16:43
12/15/17
12/15
16:43
12/15/17
16:43
Syndicate
Breaking Syndicate news story on Sino-Global »

Sino-Global files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALN

American Lorain

16:35
12/15/17
12/15
16:35
12/15/17
16:35
Hot Stocks
American Lorain regains compliance for continued listing on NYSE »

American Lorain announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKH

Black Hills

$60.02

0.55 (0.92%)

16:32
12/15/17
12/15
16:32
12/15/17
16:32
Hot Stocks
Black Hills Arkansas subsidiary requests rate review for system investments »

Black Hills Corp.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.